The following areas are of interest to the Respiratory Supported Studies Committee. These were last updated in September 2019.

[Severe Asthma/COPD/Nasal Polyposis]
• Studies aimed to identify baseline predictors of response to mepolizumab and support its use in patients with eosinophilic conditions
• Studies to provide an understanding how to stratify treatment for a patient who may be eligible for multiple add-on treatments if not controlled at GINA step 4/5
• Evaluating the effectiveness, treatment changes (i.e., OCS use) impact on QoL, and healthcare resource utilization of mepolizumab, in real-world settings, for patients with eosinophilic conditions, including patients with multiple comorbid eosinophilic conditions (i.e., asthma+nasal polyps, asthma+COPD, etc.)
• Research focused on qualitative and patient-centric outcomes in eosinophilic conditions that can improve the measurement of direct or indirect impact of mepolizumab on patients, caregivers, family, employers, and healthcare systems; including the impact and potential benefits of different modes of administration (i.e. at home or clinic administration with autoinjector)
• Studies aimed to improve the identification of patients with multiple comorbid eosinophilic conditions, or to provide a better understanding on the stratification of patients who may be eligible for mepolizumab across multiple eosinophilic conditions
• Research aimed to identify predictive models or biomarkers foreosinophilic conditions in on-going development indications (e.g. predict severe NP progression) – and to identify early response

[Disease mechanism]
• Research focused on understanding the various roles of eosinophils in varying tissue environments, including furthering the understanding of eosinophil subtypes